RECRUITINGINTERVENTIONAL
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder
Direct Transcranial Stimulation With Direct Current Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive
About This Trial
This is a single-center study about patients with severe resistant OCD. Main assumption is that performing 10 tDCS sessions with the anode positioned at the level of the right orbitofrontal cortex, and the cathode at the level of the supplementary motor area, associated with the provocation of symptoms before each session is effective in the reduction in obsessive-compulsive symptoms. After the inclusion visit, the treatment period is provided from D1 to D12 (one session per day from Monday to Friday, for two consecutive weeks, i.e. a total of ten sessions). Each tDCS session lasts 30 minutes at an intensity of 2 mA and is preceded by symptom provocation using a standardized procedure performed by trained personnel. The patients are then assessed on D42 and D102 (i.e. 1 month and 3 months after the end of the tDCS sessions).
Who May Be Eligible (Plain English)
Who May Qualify:
- Patient suffering from OCD evolving for at least 2 years diagnosed according to DSM-V criteria;
- Patient with good insight, defined by a score less than or equal to 18 at the threshold of delusions on the BABS (Brown Assessment of Beliefs Scale) insight scale;
- Absence of a current depressive episode (MADRS score \< 21) or suicidal risk (MADRS score item 10 \< 3);
- Absence of epileptic pathology;
- Chronic obsessive-compulsive disorder defined by a total YBOCS score \> 20, or a subscale score \> 15;
- Drug-resistant obsessive-compulsive disorder despite treatment with:
1. at least 2 antidepressants of the IRS type at an effective dose and for a sufficient duration
2. and/or Behavioral and Cognitive therapy for at least 1 year;
- Therapeutic stability (antidepressants) for more than 12 weeks without significant improvement. This treatment, at a fixed dose, will be maintained during the study;
- Patient aged between 18 and 70 included
- Patient who has given his/her willing to sign a consent form after having received written information on the planned procedure;
- Patient benefiting from social security or by benefiting through a third party.
Who Should NOT Join This Trial:
- Woman of childbearing age without effective means of contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
- Pregnant or nursing woman;
- Patient hospitalized under duress (SPDT, SPDRE);
- Patient under guardianship or curatorship;
- Patient with another DSM-V Axis 1 diagnosis (Schizophrenic Disorder, Bipolar Disorder, Substance Abuse or Substance Dependence).
Generalized anxiety disorder, social phobia, nicotine addiction and history of major depressive episodes are not exclusion criteria. Axis I comorbidity will be explored using MINI 5.0.0. ;
- Patient suffering from a current depressive episode;
- Patient at risk of suicide;
...See full criteria on ClinicalTrials.gov
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patient suffering from OCD evolving for at least 2 years diagnosed according to DSM-V criteria;
* Patient with good insight, defined by a score less than or equal to 18 at the threshold of delusions on the BABS (Brown Assessment of Beliefs Scale) insight scale;
* Absence of a current depressive episode (MADRS score \< 21) or suicidal risk (MADRS score item 10 \< 3);
* Absence of epileptic pathology;
* Chronic obsessive-compulsive disorder defined by a total YBOCS score \> 20, or a subscale score \> 15;
* Drug-resistant obsessive-compulsive disorder despite treatment with:
1. at least 2 antidepressants of the IRS type at an effective dose and for a sufficient duration
2. and/or Behavioral and Cognitive therapy for at least 1 year;
* Therapeutic stability (antidepressants) for more than 12 weeks without significant improvement. This treatment, at a fixed dose, will be maintained during the study;
* Patient aged between 18 and 70 included
* Patient who has given his/her informed consent after having received written information on the planned procedure;
* Patient benefiting from social security or by benefiting through a third party.
Exclusion Criteria:
* Woman of childbearing age without effective means of contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
* Pregnant or nursing woman;
* Patient hospitalized under duress (SPDT, SPDRE);
* Patient under guardianship or curatorship;
* Patient with another DSM-V Axis 1 diagnosis (Schizophrenic Disorder, Bipolar Disorder, Substance Abuse or Substance Dependence).
Generalized anxiety disorder, social phobia, nicotine addiction and history of major depressive episodes are not exclusion criteria. Axis I comorbidity will be explored using MINI 5.0.0. ;
* Patient suffering from a current depressive episode;
* Patient at risk of suicide;
* Patient with skin lesions on the scalp;
* History of head trauma;
* Patient with an intracerebral metal object
* Patient with a pacemaker;
* Presence of epileptic pathology;
* Patient in an emergency situation or unable to give personal consent
Treatments Being Tested
BEHAVIORAL
tDCS + symptoms provocation
The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
Locations (1)
Centre Hospitalier Henri Laborit
Poitiers, France